Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 17/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7018813 | 0.88 | PYGL (0.47) | PYGLMEN1RAB9AKMT2AATM | |
| SCHEMBL7019880 | 0.80 | F10 (0.51) | PYGLF10 | |
| SCHEMBL7109851 | 0.76 | PYGL (0.45) | PYGLMEN1RAB9AKMT2AATM | |
| SCHEMBL7016060 | 0.76 | ALOX5 (0.64) | KMT2A | |
| SCHEMBL7012580 | 0.75 | F10 (0.61) | PYGLF10 | |
| SCHEMBL7014369 | 0.74 | F7 (0.51) | PYGLMEN1RAB9AKMT2A | |
| SCHEMBL7016462 | 0.69 | F10 (0.51) | F10 | |
| SCHEMBL7014965 | 0.69 | F10 (0.47) | PYGLMEN1KMT2AF10 | |
| SCHEMBL7011732 | 0.68 | F10 (0.40) | PYGLMEN1KMT2AF10 | |
| SCHEMBL949393 | 0.68 | SMN1; SMN2 (0.44) | PYGLMEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | PYGL 4465/4885MEN1 1401/4885RAB9A 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.